MDWD - MediWound Ltd.

17.37
-0.120   -0.691%

Share volume: 69,050
Last Updated: 03-10-2026
Pharmaceutical Products/Medicinal Chemicals: 2.20%

PREVIOUS CLOSE
CHG
CHG%
$17.49
-0.12
-0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
55%
Profitability 50%
Dept financing 50%
Liquidity 75%
Performance 55%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
2.00%
1 Month
0.70%
3 Months
-9.81%
6 Months
-8.87%
1 Year
0.93%
2 Year
6.76%
Key data
Stock price
$17.37
P/E Ratio 
-9.93
DAY RANGE
$17.26 - $17.60
EPS 
-$0.34
52 WEEK RANGE
$14.14 - $22.50
52 WEEK CHANGE
-$2.63
MARKET CAP 
198.362 M
YIELD 
N/A
SHARES OUTSTANDING 
10.786 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-28-2025
BETA 
1.28
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$94,102
AVERAGE 30 VOLUME 
$83,856
Company detail
CEO: Ofer Gonen
Region: US
Website: mediwound.com
Employees: 80
IPO year: 2014
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Medicinal Chemicals
Sector: Manufacturing

MediWound Ltd. markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma.

Recent news